Dishman Carbogen Amcis

203.95
+16.09
(8.56%)
Market Cap
3,197.59 Cr
EPS
-9.79
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
307.98
52 Week Low
133.00
PB Ratio
0.51
Debt to Equity
0.40
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Dishman Carbogen Amcis Subsidiary Receives Drug Manufacturing License in Shanghai4 days ago
A subsidiary of Dishman Carbogen Amcis has been granted a drug manufacturing license by the National Medical Products Administration (NMPA) for its facility in Shanghai, China. This license allows the company to manufacture pharmaceutical products at the Shanghai site, potentially expanding its operations and capabilities in the Chinese market.
positive
Dishman Carbogen Amcis Subsidiary Obtains Drug Manufacturing License in China5 days ago
A subsidiary of Dishman Carbogen Amcis has received a drug manufacturing license from China's National Medical Products Administration (NMPA) for its Shanghai site. This license allows the company to manufacture pharmaceutical products in China, potentially expanding its operations in the Asian market.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61
Growth Rate
Revenue Growth
8.33 %
Net Income Growth
415.10 %
Cash Flow Change
44.37 %
ROE
435.29 %
ROCE
-107.32 %
EBITDA Margin (Avg.)
-19.32 %

Quarterly Financial Results

Quarterly Financials
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
419
368
440
372
491
345
440
446
468
455
447
441
631
509
456
528
533
483
454
478
535
561
469
581
573
546
623
646
625
730
595
657
662
525
796
690
Expenses
318
271
321
263
388
270
311
339
330
362
319
346
480
403
322
417
405
431
359
406
463
450
362
453
559
452
535
529
613
602
529
610
595
500
645
542
EBITDA
101
97
118
109
103
75
129
107
138
93
128
95
151
107
135
111
128
52
95
72
72
111
106
129
14
94
88
118
13
128
66
47
67
25
151
148
Operating Profit %
22 %
25 %
25 %
26 %
20 %
20 %
28 %
21 %
27 %
19 %
26 %
19 %
21 %
20 %
29 %
20 %
21 %
9 %
18 %
13 %
12 %
18 %
21 %
19 %
2 %
16 %
13 %
17 %
1 %
17 %
10 %
6 %
9 %
4 %
18 %
21 %
Depreciation
30
51
55
51
57
51
55
55
51
54
58
58
71
67
70
72
74
74
78
79
77
75
74
75
84
75
80
50
76
70
75
80
85
71
72
72
Interest
21
23
20
13
10
11
13
13
11
15
15
14
13
14
17
11
20
12
13
14
9
12
14
15
16
19
20
22
24
29
28
33
31
32
37
49
Profit Before Tax
67
36
51
50
83
14
74
68
75
58
71
75
106
46
65
51
35
-34
4
-22
-14
24
19
39
-85
-0
-12
46
-88
30
-36
-66
-49
-78
42
27
Tax
17
6
13
17
40
1
26
26
24
18
27
23
30
12
24
18
-15
-12
-3
-6
121
8
7
3
-41
-4
-2
-1
-17
13
5
-7
21
0
9
22
Net Profit
50
30
38
33
43
13
48
42
51
40
44
51
76
34
41
33
50
-21
7
-16
-135
16
11
35
-45
4
-10
47
-71
17
-41
-60
-70
-78
33
5
EPS in ₹
6.17
1.88
2.37
2.01
2.65
0.81
3.00
2.60
3.17
2.46
2.73
3.18
4.70
2.13
2.55
2.04
3.11
-1.37
0.47
-1.02
-8.61
1.02
0.71
2.26
-2.85
0.26
-0.64
3.00
-4.51
1.08
-2.61
-3.80
-4.46
-4.95
2.11
0.30

Balance Sheet

Balance Sheet
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
6,593
7,177
7,329
8,200
8,366
8,638
9,454
9,581
Fixed Assets
4,852
5,066
5,098
5,678
5,698
5,773
6,188
6,724
Current Assets
1,245
1,546
1,554
1,779
1,704
1,839
1,918
1,928
Capital Work in Progress
133
151
175
234
486
780
1,043
646
Investments
40
196
167
191
172
324
249
102
Other Assets
1,569
1,764
1,889
2,097
2,010
1,761
1,973
2,109
Total Liabilities
6,593
7,177
7,329
8,200
8,366
8,638
9,454
9,581
Current Liabilities
994
1,178
1,198
1,569
1,290
1,420
1,798
2,555
Non Current Liabilities
786
891
751
916
1,377
1,669
1,845
1,399
Total Equity
4,814
5,107
5,379
5,715
5,699
5,549
5,810
5,628
Reserve & Surplus
4,814
5,075
5,347
5,684
5,668
5,518
5,778
5,596
Share Capital
0
32
32
31
31
31
31
31

Cash Flow

Cash Flow
2011
2012
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-3
-19
59
7
11
46
122
-133
22
132
Investing Activities
-231
-104
-107
-297
-169
-442
-380
-619
-494
-230
Operating Activities
203
154
303
226
282
585
513
355
266
384
Financing Activities
26
-68
-137
78
-102
-98
-11
130
250
-22

Share Holding

% Holding
Apr 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
63.17 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
59.32 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.80 %
8.61 %
8.70 %
8.04 %
8.17 %
8.74 %
DIIs
12.80 %
8.85 %
6.66 %
6.05 %
6.18 %
6.75 %
6.54 %
4.28 %
3.87 %
2.56 %
3.14 %
3.52 %
3.69 %
2.37 %
1.48 %
1.23 %
1.42 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.93 %
21.60 %
22.62 %
24.75 %
24.20 %
23.55 %
23.73 %
25.85 %
25.66 %
24.61 %
24.57 %
24.64 %
24.54 %
25.17 %
27.10 %
27.43 %
26.22 %
Others
13.09 %
10.24 %
11.40 %
9.87 %
10.30 %
10.37 %
10.42 %
10.55 %
11.15 %
13.50 %
12.97 %
3.72 %
3.85 %
4.45 %
4.06 %
3.85 %
4.29 %
No of Share Holders
43,186
58,738
54,077
60,726
54,662
56,322
56,986
59,654
61,175
56,583
56,221
56,272
52,336
50,656
53,683
55,280
52,822

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.2 0.00 0.2 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.37 0.00 0.37 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015: COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD. RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SI5 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20185 days ago
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 01, 2025
Board Meeting Outcome for OUTCOME OF BOARD MEETING: CESSATION AND APPOINTMENT OF INDEPENDENT DIRECTORSApr 01, 2025
Board Meeting Outcome for OUTCOME OF BOARD MEETING: CESSATION AND APPOINTMENT OF INDEPENDENT DIRECTORSApr 01, 2025
Announcement under Regulation 30 (LODR)-AllotmentMar 26, 2025
PRESS RELEASE REGARDING COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS. RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINT-BEAUZIRE SITE FRANCEMar 24, 2025
DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015: COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS SAS. RECEIVED CERTIFICATE OF GMP COMPLIANCE FROM NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS FOR ITS SAINMar 19, 2025
Closure of Trading WindowMar 19, 2025
Board Meeting Outcome for BOARD APPROVES ISSUE OF RATED LISTED SENIOR SECURED REDEEMABLE TAXABLE NON-CONVERTIBLE DEBENTURES AGGREGATING UP TO RS. 50 CRORESMar 12, 2025
Board Meeting Intimation for Consideration And Approval Of The Proposal Of Fund Raising By Way Of Issuance Of Non-Convertible Debentures By Way Of Private Placement Subject To Such Regulatory Or Statutory Approvals As May Be RequiredMar 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2024Feb 12, 2025
UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2024Feb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Board Meeting Intimation for Considering Take On Record And Approve The Un-Audited Financial Results Of The Company For The Third Quarter Ended On 31St December 2024Feb 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotFeb 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJan 31, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 31, 2024
Announcement under Regulation 30 (LODR)-CessationDec 14, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 20, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 19, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 14, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 13, 2024
Board Meeting Outcome for OUTCOME OF BOARD MEETING ALONGWITH UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30/09/2024Nov 13, 2024
OUTCOME OF BOARD MEETING ALONGWITH UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30/09/2024Nov 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2024
Board Meeting Intimation for Considering, Take On Record And Approve The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2024Nov 07, 2024
DISCLOSURE UNDER REGULATIONS 30 OF SEBI (LODR) REGULATIONS, 2015: INTIMATION OF CHANGE IN SENIOR MANAGEMENT PERSONNELOct 10, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Compliance-57 (5) : intimation after the end of quarterOct 07, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 27, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 27, 2024
Closure of Trading WindowSep 25, 2024
Compliance-57 (4) : Prior intimation to the beginning of the quarterSep 21, 2024
ANNUAL GENERAL MEETING AND E-VOTING NOTICE - NEWS PAPER ADVERTISEMENTSep 04, 2024
Business Responsibility and Sustainability Reporting (BRSR)Sep 03, 2024
Reg. 34 (1) Annual Report.Sep 03, 2024
NEWSPAPER ADVERTISEMENT FOR INFORMATION REGARDING THE 17TH ANNUAL GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING OR OTHER AUDIO VISUAL MEANSAug 31, 2024

Technical Indicators

RSI(14)
Neutral
44.48
ATR(14)
Less Volatile
13.26
STOCH(9,6)
Neutral
29.16
STOCH RSI(14)
Oversold
19.19
MACD(12,26)
Bearish
-2.62
ADX(14)
Weak Trend
20.70
UO(9)
Bearish
44.20
ROC(12)
Downtrend And Accelerating
-12.52
WillR(14)
Neutral
-57.33